Practical experience of ustekinumab in patients with moderate-to-severe psoriasis who had inadequate therapeutic response to previous tumor necrosis factor blockers

Background/Objective(s): Few studies have evaluated the therapeutic response among switchers of biologics in patients with psoriasis. We report our experience of ustekinumab in patients with psoriasis who did not respond adequately to tumor necrosis factor (TNF) blockers treatment previously. Method...

Cijeli opis

Bibliografski detalji

Glavni autori:	Tzu-Chang Wang, Hsien-Yi Chiu, Ting-Shun Wang, Tsen-Fang Tsai
Format:	Artigo
Jezik:	Inglês
Izdano:	Wolters Kluwer Medknow Publications 2015-03-01
Serija:	Dermatologica Sinica
Teme:	adalimumab biologics switch etanercept PASI (Psoriasis Area and Severity Index) psoriasis ustekinumb
Online pristup:	http://www.sciencedirect.com/science/article/pii/S1027811714000536
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!